First Trust NYSE Arca Biotech ETF (FBT)

Add to Watchlists
Create an Alert
125.63 -0.58  -0.46% NYSE Arca Oct 18, 20:00 Delayed 2m USD
View Full Chart
Price Chart

Key Stats

Net Asset Value 125.70
Discount or Premium to NAV -0.06%
Turnover Ratio 37.00%
1 Year Fund Level Flows -1.013B

Performance & Returns

  Total Return (Price) Total Return (NAV) Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M -3.98% -3.98% -1.54% 85
3M -10.10% -10.10% -4.36% 88
6M -7.98% -7.99% 3.04% 92
YTD 1.15% 1.17% 8.66% 96
1Y -14.20% -14.13% -3.60% 95
3Y 11.53% 11.54% 9.56% 34
5Y 7.02% 7.07% 8.21% 61
10Y 16.11% 16.12% 13.86% 15
15Y -- -- 10.70% --
20Y -- -- 10.32% --
As of Oct. 18, 2019. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash 0.05% 0.05% 0.00%
Stock 99.95% 99.95% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of Oct. 17, 2019

Region Exposure

Americas 96.62%
North America 96.62%
Latin America 0.00%
Greater Europe 3.38%
United Kingdom 0.00%
Europe Developed 3.38%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.00%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.00%
Market Classification
% Developed Markets 100.0%
% Emerging Markets 0.00%
As of Oct. 17, 2019. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of Oct. 17, 2019

Stock Market Capitalization

Giant 4.13%
Large 28.04%
Medium 47.41%
Small 20.42%
Micro 0.00%
As of Oct. 17, 2019

Stock Style Exposure

Large Cap Value 11.28%
Large Cap Blend 10.03%
Large Cap Growth 10.85%
Mid Cap Value 0.00%
Mid Cap Blend 2.58%
Mid Cap Growth 44.83%
Small Cap Value 0.00%
Small Cap Blend 3.92%
Small Cap Growth 16.50%
As of Oct. 17, 2019
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
ACAD ACADIA Pharmaceuticals Inc 5.63% 39.95 -0.08%
SGEN Seattle Genetics Inc 4.14% 87.40 +1.70%
AMGN Amgen Inc 4.13% 202.72 -0.41%
NBIX Neurocrine Biosciences Inc 4.09% 95.78 -1.10%
ALNY Alnylam Pharmaceuticals Inc 3.93% 84.78 +3.54%
UTHR United Therapeutics Corp 3.92% 82.14 +0.58%
ILMN Illumina Inc 3.83% 309.44 -0.36%
VRTX Vertex Pharmaceuticals Inc 3.69% 176.23 -0.84%
REGN Regeneron Pharmaceuticals Inc 3.65% 300.19 -0.46%
CRL Charles River Laboratories International Inc 3.63% 134.28 -1.32%
As of Oct. 17, 2019
Advertisement

Basic Info

Investment Strategy
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Prospectus Objective Specialty - Health
Fund Owner Firm Name First Trust
Benchmark Index
NYSE Arca Biotechnology TR USD 100.0%
Reports
One Page Report Download

Manager Info

Name Tenure
Chris Peterson 3.12 yrs
Daniel Lindquist 12.87 yrs
David McGarel 12.87 yrs
Jon Erickson 12.87 yrs
Roger Testin 12.87 yrs
Stan Ueland 12.48 yrs

Net Fund Flows

1M -885.53M
3M -983.93M
6M -977.46M
YTD -697.69M
1Y -1.013B
3Y 917.46M
5Y 620.39M
10Y 1.590B
As of Sept. 30, 2019

Risk Info

Beta (5Y) 1.470
Max Drawdown (All) 40.51%
Historical Sharpe Ratio (10Y) 0.7631
Historical Sortino (All) 0.8953
30-Day Rolling Volatility 18.88%
Daily Value at Risk (VaR) 1% (All) 4.29%
Monthly Value at Risk (VaR) 1% (All) 20.34%

Fundamentals

Dividend Yield TTM (10-18-19) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Weighted Average PE Ratio 21.28
Weighted Average Price to Sales Ratio 6.199
Weighted Average Price to Book Ratio 4.345
Weighted Median ROE 0.18%
Weighted Median ROA -4.96%
Forecasted Dividend Yield 0.36%
Forecasted PE Ratio 18.84
Forecasted Price to Sales Ratio 3.858
Forecasted Price to Book Ratio 2.845
Number of Holdings 31
As of Oct. 17, 2019

Growth Estimates

Forecasted 5 Yr Earnings Growth 18.61%
Forecasted Book Value Growth 13.00%
Forecasted Cash Flow Growth 6.55%
Forecasted Earnings Growth 20.06%
Forecasted Revenue Growth 15.80%
As of Oct. 17, 2019

Comparables

Edit

Attributes

Key Dates
Inception Date 6/19/2006
Termination Date
Last Annual Report Date 12/31/2018
Last Prospectus Date 5/1/2019
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.